Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)
NCT ID: NCT02837198
Last Updated: 2018-08-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
24 participants
INTERVENTIONAL
2016-07-31
2018-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In addition, to investigate the additive effects of the combination of FYU-981 and topiroxostat administered orally to male hyperuricemic patients with uric acid-overproduction type.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)
NCT03375632
Study of FYU-981 in Hyperuricemia With or Without Gout
NCT02344862
Study of FYU-981 in Hyperuricemia With or Without Gout
NCT02416167
Study of FYU-981 in Hyperuricemia With or Without Gout
NCT03006445
Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
NCT03100318
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Uric acid-overproduction Type
FYU-981
FYU-981
Uric acid- underexcretion Type
FYU-981
FYU-981
Uric acid-overproduction Type (combination)
FYU-981 , Topiroxostat
FYU-981
Topiroxostat
Uric acid- underexcretion Type2
FYU-981
FYU-981
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FYU-981
Topiroxostat
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Serum urate level: \>= 7.0mg/dL in patients
* Disease Type: Uric acid-overproduction Type or Uric acid-underexcretion Type
Exclusion Criteria
* Mixed type in the classification of hyperuricemia
20 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fuji Yakuhin Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tokyo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Okui D, Sasaki T, Fushimi M, Ohashi T. The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor. Clin Exp Nephrol. 2020 Mar;24(Suppl 1):92-102. doi: 10.1007/s10157-019-01817-3. Epub 2019 Nov 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FYU-981-008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.